These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25405974)

  • 1. Pharmaceuticals in the environment: scientific evidence of risks and its regulation.
    Küster A; Adler N
    Philos Trans R Soc Lond B Biol Sci; 2014 Nov; 369(1656):. PubMed ID: 25405974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental impact assessment and control of pharmaceuticals: the role of environmental agencies.
    Adler NE; Koschorreck J; Rechenberg B
    Water Sci Technol; 2008; 57(1):91-7. PubMed ID: 18192745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the regulatory environmental risk assessment of human pharmaceuticals: Required changes in the new legislation.
    Gildemeister D; Moermond CTA; Berg C; Bergstrom U; Bielská L; Evandri MG; Franceschin M; Kolar B; Montforts MHMM; Vaculik C
    Regul Toxicol Pharmacol; 2023 Aug; 142():105437. PubMed ID: 37354938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBT assessment and prioritization of contaminants of emerging concern: Pharmaceuticals.
    Sangion A; Gramatica P
    Environ Res; 2016 May; 147():297-306. PubMed ID: 26921826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the regulatory outline of ecopharmacovigilance of pharmaceuticals in Europe, USA, Japan and Australia.
    Jose J; Sandra Pinto J; Kotian B; Mathew Thomas A; Narayana Charyulu R
    Sci Total Environ; 2020 Mar; 709():134815. PubMed ID: 31887508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Environmental risk analysis and prioritization of pharmaceuticals in a developing world context.
    Mansour F; Al-Hindi M; Saad W; Salam D
    Sci Total Environ; 2016 Jul; 557-558():31-43. PubMed ID: 26994791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International scientists' priorities for research on pharmaceutical and personal care products in the environment.
    Rudd MA; Ankley GT; Boxall AB; Brooks BW
    Integr Environ Assess Manag; 2014 Oct; 10(4):576-87. PubMed ID: 24954797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment for ecotoxicity of pharmaceuticals--an emerging issue.
    Kar S; Roy K
    Expert Opin Drug Saf; 2012 Mar; 11(2):235-74. PubMed ID: 22166011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving environmental risk assessment of human pharmaceuticals.
    Ågerstrand M; Berg C; Björlenius B; Breitholtz M; Brunström B; Fick J; Gunnarsson L; Larsson DG; Sumpter JP; Tysklind M; Rudén C
    Environ Sci Technol; 2015 May; 49(9):5336-45. PubMed ID: 25844810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of prioritization approaches to optimize environmental monitoring and testing of pharmaceuticals.
    Burns EE; Carter LJ; Snape J; Thomas-Oates J; Boxall ABA
    J Toxicol Environ Health B Crit Rev; 2018; 21(3):115-141. PubMed ID: 29714645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, assessment and management of "endocrine disruptors" in wildlife in the EU substance legislation--discussion paper from the German Federal Environment Agency (UBA).
    Frische T; Bachmann J; Frein D; Juffernholz T; Kehrer A; Klein A; Maack G; Stock F; Stolzenberg HC; Thierbach C; Walter-Rohde S
    Toxicol Lett; 2013 Dec; 223(3):306-9. PubMed ID: 23500481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation.
    Besse JP; Garric J
    Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences with the OECD 308 transformation test: a human pharmaceutical perspective.
    Ericson JF; Smith RM; Roberts G; Hannah B; Hoeger B; Ryan J
    Integr Environ Assess Manag; 2014 Jan; 10(1):114-24. PubMed ID: 23794155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Environmental risk assessment of medicinal products for human use according to European Commission recommendations.
    Huschek G; Hansen PD; Maurer HH; Krengel D; Kayser A;
    Environ Toxicol; 2004 Jun; 19(3):226-40. PubMed ID: 15101038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental risk assessment of veterinary pharmaceuticals in the EU: reply to Montforts and de Knecht.
    Long C; Crane M
    Toxicol Lett; 2003 May; 142(3):219-25. PubMed ID: 12691715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human pharmaceutical products in the environment - the "problem" in perspective.
    Taylor D; Senac T
    Chemosphere; 2014 Nov; 115():95-9. PubMed ID: 24525259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Upstream Strategies for the Mitigation of Pharmaceuticals in the Aquatic Environment: a Brief Review.
    Blair BD
    Curr Environ Health Rep; 2016 Jun; 3(2):153-60. PubMed ID: 27068434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental risk assessment of veterinary medicinal products in the EU--a regulatory perspective.
    Koschorreck J; Koch C; Rönnefahrt I
    Toxicol Lett; 2002 May; 131(1-2):117-24. PubMed ID: 11988364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the environmental risk assessment of pharmaceuticals: Facts and fantasies.
    Tarazona JV; Escher BI; Giltrow E; Sumpter J; Knacker T
    Integr Environ Assess Manag; 2010 Jul; 6 Suppl():603-13. PubMed ID: 19886731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prioritizing human pharmaceuticals for ecological risks in the freshwater environment of Korea.
    Ji K; Han EJ; Back S; Park J; Ryu J; Choi K
    Environ Toxicol Chem; 2016 Apr; 35(4):1028-36. PubMed ID: 26348846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.